Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 23, 2025

Costco: Buy It Again Before Everyone Else Catches On

View original at finance.yahoo.com
Costco: Buy It Again Before Everyone Else Catches On This article first appeared on GuruFocus. Costco (COST) is one of my favorite stocks to generally own, sometimes trade…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Fed's dot plot suggests three more rate cuts of 25 bps through end of next year

    80% confidence
  • Author assumes Costco's retail business at 2% operating margin is worth nothing to shareholders in valuation model

    80% confidence
  • The trip to $500 billion market cap could play out over 12 to 24 months

    80% confidence
  • Membership fee increases of around 10% occur every six or seven years

    80% confidence
  • Best-case scenario suggests opportunity for membership increase of 50% in four developed countries alone

    80% confidence
  • Costco has upside potential of 22% to $500 billion market cap, or even more in best-case scenario

    80% confidence
  • The best opportunity to buy Costco and earn strong double-digit returns is well behind us now

    80% confidence
  • Costco's membership fees have historically grown at a pace surpassing 5% in most recent fiscal year

    80% confidence
  • Costco stock could prove countercyclical if market hits a pothole

    80% confidence
  • Costco has potential to operate 520 stores in UK, Germany, Australia and Japan versus current 80

    80% confidence
  • Costco has a membership renewal rate of more than 92%

    80% confidence
  • A 10-bp reduction in risk-free rate would add roughly 10% to upside opportunity

    80% confidence
  • Costco remains misunderstood by too many potential investors despite efficient market premise

    80% confidence
  • Membership revenues carry very little direct costs and flow almost cleanly to pretax income

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com